Analyst Price Target is $4.67
▲ +348.72% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kintara Therapeutics in the last 3 months. The average price target is $4.67, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 348.72% upside from the last price of $1.04.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Kintara Therapeutics. This Buy consensus rating has held steady for over two years.
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. It focuses on VAL-083 and REM-001 pipelines. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.